A human cardiomyocyte screen identifies optimized lipid nanoparticles for in vivo cardiac gene editing
Open Access
- 18 May 2026
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (21)
Abstract
RNA therapeutics offer promising potential for treating heart disease; however, their clinical application has been limited by insufficient cardiac delivery. Here, we developed a screening platform using human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) to identify human cardiotropic lipid nanoparticles (LNPs). By screening a chemically diverse LNP library, we identified a lead LNP, 18:1 TAP10, with potent human cardiac transfection capability. Using the Ai14 LoxP-Stop-LoxP-tdTomato reporter mouse model, we assessed 18:1 TAP10 LNP delivery of Cre mRNA in vivo via four administration routes (intravenous, intrathoracic, intracoronary, and intramyocardial (IM)) and found that each administration path enabled both the spatial distribution and cellular tropism in the heart to varying degrees. While all routes achieved robust transfection across non-CM populations (up to 40% in endothelial cells), IM injection notably enabled substantial CM transfection (36% at injection site, 13% distally). To demonstrate therapeutic potential, 18:1 TAP10 LNPs were used to deliver adenine base editor (ABE) components to Duchenne muscular dystrophy (DMD) patient-derived hiPSC-CMs, resulting in 80% on-target gene correction and restoration of dystrophin expression. In a humanized DMD mouse model, we observed dystrophin-positive cardiomyocytes in the injected left ventricle following IM administration of LNP-ABE. This work establishes a human cell-based platform for discovering organ-tropic delivery vehicles and highlights LNPs as a potential modality for therapeutic mRNA delivery and gene editing in the heart.Keywords
Funding Information
- National Institute of Biomedical Imaging and Bioengineering (EB025192-01A1)
- National Cancer Institute (CA269787-01)
- National Heart, Lung, and Blood Institute (R01HL130253)
- National Heart, Lung, and Blood Institute (R01HL157281)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P50HD087351)
- Welch Foundation (1-0025)
- Welch Foundation (I-2123-20220031)
This publication has 37 references indexed in Scilit:
- Cardiac safety of fordadistrogene movaparvovec gene therapy in Duchenne muscular dystrophy: Initial observations from a phase 1b trialMolecular Therapy, 2025
- Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021The Lancet, 2024
- Lethal immunotoxicity in high-dose systemic AAV therapyMolecular Therapy, 2023
- Spleen SORT LNP Generated in situ CAR T Cells Extend Survival in a Mouse Model of Lymphoreplete B Cell LymphomaAngewandte Chemie International Edition, 2023
- Single-swap editing for the correction of common Duchenne muscular dystrophy mutationsMolecular Therapy Nucleic Acids, 2023
- Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass graftingMolecular Therapy, 2022
- A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editingMolecular Therapy Nucleic Acids, 2022
- The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungsJournal of Controlled Release, 2022
- Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library ScreeningMolecular Therapy, 2019
- mRNA-Based Protein Replacement Therapy for the HeartMolecular Therapy, 2019